NCT00199381View on ClinicalTrials.gov

An Extension of Istradefylline in North American Parkinson's Disease Patients Who Have Completed Study 6002-INT-001

PHASE3TerminatedINTERVENTIONAL

Enrollment

504

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions

Parkinson's Disease

Interventions

DRUG

Istradefylline

Oral istradefylline (KW-6002) 20 or 40 mg once daily.

Trial Locations (1)

08540

Kyowa Pharmaceutical Inc., Princeton

Sponsors

Lead Sponsor

Kyowa Kirin, Inc.

All Listed Sponsors

collaborator

Kyowa Kirin Co., Ltd.

INDUSTRY

lead

Kyowa Kirin, Inc.

INDUSTRY